Year None202420232022202120202019 Sep 19, 2024 Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTE Sep 05, 2024 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Sep 05, 2024 Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255 Aug 28, 2024 Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Ef Aug 22, 2024 Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference Aug 14, 2024 Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update Aug 02, 2024 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 01, 2024 Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024 Jul 29, 2024 Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc. First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Next page next › Last page last » Displaying 10 - 18 of 53
